Van what do you think? Sunrun Inc. (RUN) $23-$33 trade<------------- NasdaqGS - NasdaqGS Real Time Price. 23.11-2.73 (-10.55%) As of 12:26PM EDT.
Those were sells Stoney. If the children wanted to buy, It was $2.38 Barely up on the day. Premarket when you post:
Van it was $2 in the pre. // I gave you the trade. Big Pete got in and it wasn't no 300 shares. More like 3,000 your numbers are all off. As usual. I do think he bought some at the open as well. Why don't you say amazing job on a day like today. And you can go back and read my work on the name in prior threads. It's a big gainer for GBA! And that should be celebrated. You come off as bitter! AMLX story The Food and Drug Administration pushed its review date for Amylyx Pharmaceuticals' (AMLX) controversial ALS treatment on Friday, and the biotech stock skyrocketed. The news gave investors fresh hope after a panel of FDA experts decided there's not enough evidence to support the drug's benefit in amyotrophic lateral sclerosis. Also known as Lou Gehrig's disease, ALS is a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord. Previously, the FDA planned to make a decision on Amylyx's drug, dubbed AMX0035, in late June. But Amylyx recently submitted additional clinical data, and the agency needs three more months to review it. "Following the disappointing (advisory committee meeting) the investment community has expected AMX0035 to not get approved by the FDA, but it appears that the FDA is still struggling with its decision," SVB Securities analyst Marc Goodman said in a report to clients. On the stock market today, the biotech stock soared 26.4 to 12.35. At one point, shares rose nearly 43% during the regular session. Biotech Stock Trends Down Patient advocates have pushed for the FDA to approve Amylyx's drug. One expert speaking at the recent FDA advisory committee meeting argued it's comprised of two ingredients already on the open market. Still, just four out of 10 panelists voted in favor of the drug's benefit. In a study called Centaur, the medicine helped improve muscle function. But it's unclear whether it prolonged survival. Amylyx is running another study called Phoenix to confirm the drug's benefit, but it asked for early approval based on the Centaur study. Following the negative advisory committee vote on March 30, Amylyx shares plummeted nearly 14%. The biotech stock has continued to trend down since then.
VOL & price alert-** Cogent Biosciences, Inc. (COGT)- i don't know the story... NasdaqGS - NasdaqGS Real Time Price. 8.77+0.90 (+11.40%) As of 12:48PM EDT. Market open.
This is very interesting we had this name last week as a gummy! It gapped up and got away from us!!! we are always on the cusp aren't we... Cogent Biosciences announces $125M common stock offering 06:13 COGT Normally a neg <-- why up? Cogent Biosciences announced that it has commenced an underwritten public offering of $125M of shares of its common stock. Cogent intends to use the net proceeds from the offering for development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes. Jefferies, Piper Sandler & Co. and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. Show Related Items >> Friday Cogent Biosciences price target raised to $15 from $14 at SVB Leerink 11:24 COGT SVB Leerink analyst Christopher Liu raised the firm's price target on Cogent Biosciences to $15 from $14 and keeps an Outperform rating on the shares after the company announced initial data for bezuclastinib from the Phase 2 APEX trial in advanced systemic mastocytosis patients. Liu believes that these data across dose levels demonstrate an encouraging profile, suggesting safety and differentiation vs. Ayvakit, and that the favorable safety profile could read through to the non-advanced/indolent systemic mastocytosis setting, the analyst tells investors in a research note. Show Related Items >> Cogent Biosciences should be up 'sharply' on data, says Piper Sandler 08:59 COGT Piper Sandler analyst Christopher Raymond is "incrementally positive" on Cogent Biosciences and expects shares to be up "sharply" on the initial data from bezuclastinib's Phase 2 APEX trial in advanced systemic mastocytosis. While it is just 11 patients and duration of treatment is relatively short, the treatment effect is "striking" as all patients achieved at least a 50% reduction in serum tryptase, and this reduction was seen very quickly as median time to response was just over a week, Raymond tells investors in a research note. He thinks bezuclastinib is emerging as a "best-in-class treatment" for systemic mastocytosis. The analyst has an Overweight rating on Cogent Biosciences with a $22 price target. The stock in premarket trading is up 14% to $5.64.
We can't buy at the high of the day today but.. the tech set up is perfect. Cogent Biosciences, Inc. (COGT)<--------- watch list! NasdaqGS - NasdaqGS Real Time Price. 8.82+0.95 (+12.07%) As of 12:53PM EDT.
Well I just looked through all my paper work and it seems OPTN was $3.20 when I bought it! So much for that. At least we have today's action. Hummmmmmmm. I could of sworn I had abetter price. Market sucks.
It was a good call. It could have been bought after the bell at $2. Your IMAX is $15. That might bounce. I don't know what their China revenue is though. You mentioned China once. I didn't know they operated there.